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Objective. Giant cell (temporal) arteritis (GCA) is
a vasculitis that mainly affects the large and medium
arteries, especially the branches of the proximal aorta.
Interleukin-32 (IL-32) is a recently described Th1 pro-
inflammatory cytokine, and is mainly induced by
interferon- (IFN), IL-1, and tumor necrosis factor 
(TNF). This study was undertaken to investigate the
expression and tissue distribution of IL-32 in artery
biopsy specimens from patients with GCA.
Methods. Quantitative gene expression analysis
of IL-32, IL-1, TNF, IFN, IL-6, and IL-27 was
performed in artery biopsy specimens obtained from 18
patients with GCA and 15 controls. Immunohistochem-
istry analysis was performed to evaluate IL-32 tissue
distribution and identify IL-32–producing cells. Circu-
lating Th1 lymphocytes were evaluated by flow cytom-
etry.
Results. We demonstrated a strong and signifi-
cant up-regulation of IL-32 at both the messenger RNA
and protein levels in the artery biopsy samples from
patients with GCA. IL-32 was abundantly expressed by
vascular smooth muscle cells of inflamed arteries and
neovessels within inflammatory infiltrates. IL-32 ex-
pression strongly correlated with the intensity of the
systemic inflammatory response. IL-32 overexpression
was accompanied by strong overexpression of Th1 cyto-
kines, such as IFN and IL-27p28, in inflamed arteries
from GCA patients. The Th1 lymphocyte population was
also expanded among peripheral blood mononuclear
cells from GCA patients and produced higher amounts
of IL-32 compared to controls.
Conclusion. Our findings indicate that overex-
pression of IL-32 together with a clear Th1 response
immunologically characterizes the inflammatory re-
sponse in GCA. In particular, IL-32 seems to be an
important mediator of artery inflammation in GCA.
In giant cell (temporal) arteritis (GCA), inflam-
mation mainly affects the large and medium muscular
arteries, especially the proximal aorta and its branches.
One or more systemic manifestations are present in
most patients and indicate the presence of a systemic
inflammatory response (1).
The exact mechanisms that contribute to the
pathogenesis of GCA are still largely unknown. It is well
accepted, however, that inflammatory cellular infiltrates,
mainly T lymphocytes and macrophages and their exten-
sive production of proinflammatory mediators such as
tumor necrosis factor  (TNF), interleukin-1 (IL-1),
and IL-6, play a major role in the regulation of arterial
immune responses (1). GCA has previously been as-
cribed to a Th1 response, based on a study demonstrat-
ing that interferon- (IFN) is a dominant cytokine in
the inflamed arteries (2). In addition, it has been re-
cently demonstrated that another proinflammatory cy-
tokine, IL-17, is produced concomitantly with IFN in
the inflamed arteries of GCA patients, contributing to
the systemic and vascular manifestations of the disease
(3).
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IL-32 is a recently described Th1-related pro-
inflammatory cytokine, and has important functions
in both innate and immune responses; its expression
is induced by Th1 cytokines, such as IL-1, TNF, and
IFN (4). IL-32 is also constitutively produced by
human endothelial cells, indicating that it is a critical
regulator of endothelial function through regulation of
coagulation, endothelial cell activation, and atheroscle-
rosis (5–7).
The role of IL-32 in human inflammatory dis-
eases, such as Crohn’s disease (8) and rheumatoid
arthritis (RA) (9–12), has been extensively demon-
strated, identifying IL-32 as a potential therapeutic
target in chronic inflammation. Whether this cytokine
could be implicated in the immune responses that are
characteristic of GCA still remains to be investigated. In
the present study, we investigated the expression of
IL-32 in the context of Th1 response in temporal arterial
biopsy specimens from patients with GCA. Since IL-27,
a cytokine functionally and structurally related to IL-12,
has been proposed as a critical factor for early Th1
differentiation (13), we also studied IL-27 expression.
PATIENTS AND METHODS
Patients. Eighteen consecutive patients (14 women, 4
men) with biopsy-proven GCA were studied. Their median age
was 77 years (range 60–87 years), and their erythrocyte
sedimentation rate (ESR) was 80 mm/hour (range 77–120).
Headache and temporal artery tenderness were present in 15
of 18 patients. Decreased or absent temporal artery pulsation
was present in 10 of 18 patients. Patients were diagnosed as
having biopsy-proven GCA if histologic examination of the
temporal artery biopsy specimen showed disruption of the
internal elastic lamina, with infiltration of mononuclear cells
into the arterial wall, with or without giant cells. All studied
samples were obtained from untreated patients. At the time of
diagnosis, 6 patients had experienced vision loss. Five patients
had associated polymyalgia rheumatica (PMR).
Four parameters (score range 0–4), as described by
Cid et al (14), were used to evaluate the baseline inflammatory
response at diagnosis: fever, weight loss, an ESR of 85
mm/hour, and a hemoglobin level of 11.0 gm/dl. A strong
clinical inflammatory response as well as a high inflammatory
reaction demonstrated by laboratory results (14) were present
in 6 of the 18 patients. After diagnosis, GCA patients were
treated with prednisone at an initial dosage of 50 mg/day.
Prednisone was tapered in all patients according to the same
fixed schedule, starting after 1 month of therapy if symptoms
had resolved.
For controls, we obtained 15 histologically normal
temporal artery samples from 15 consecutive patients who had
been suspected of having GCA but who had negative biopsy
results. They were matched by sex and age with the biopsy-
proven GCA group (12 women, 3 men, median age 75.8 years
[range 66–85 years]). The ultimate diagnoses in these patients
were fever of unknown origin (5 patients), isolated PMR (3
patients), large-vessel vasculitis involving the thoracic aorta
and its branches but sparing the temporal artery (1 patient),
and nonspecific headache in the presence of osteoarthritis (6
patients). From 11 patients with biopsy-proven GCA and 5
controls, total RNA could be extracted from frozen fragments
of the temporal artery biopsy specimens that were excised
before treatment was begun. This study was approved by the
local ethics committee and all patients provided informed
consent for the collection and storage of biologic material.
RNA extraction from temporal artery biopsy speci-
mens and quantitative reverse transcriptase–polymerase
chain reaction (PCR) for IL-32, IL-6, transforming growth
factor , IL-1, TNF, IFN, and IL-27p28. Soon after
removal, temporal artery biopsy specimens were stored in
RNAlater solution (Applied Biosystems). Each sample was
lysed in a tissue homogenizer, and RNA was extracted using
the commercially available illustra RNAspin Mini Isolation
Kit, according to the instructions of the manufacturer (GE
Healthcare). Total RNA was reverse-transcribed to comple-
mentary DNA using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). Samples were stored at
–20°C until use. For quantitative TaqMan real-time PCR,
Master Mix and TaqMan gene expression assay kits for
GAPDH control and for IL-6 (Hs00174131_m1), IL-32
(Hs00170403_m1), IL-1 (Hs00174097_m1), TNF
(Hs00174128_m1), IFN (Hs00989291_m1), IL-6
(Hs00174131_m1), and IL-27p28 (Hs00377366_m1) were ob-
tained from Applied Biosystems. Experiments on each sample
were run in triplicate using the Step-One Real-Time PCR
system (Applied Biosystems). Relative changes in gene expres-
sion between control and arteritis samples were determined
using the Ct method. Levels of the target transcript were
normalized to GAPDH endogenous control, expressed consis-
tently in both groups (Ct). For Ct values, additional
subtractions were performed between arteritis and control Ct
values. Final values were expressed as the fold induction.
Immunohistochemistry analysis of GCA biopsy speci-
mens. Tissue samples were immediately fixed with 4% form-
aldehyde and embedded in paraffin. Immunohistochemistry
analysis for IL-32 was performed on 5-m–thick paraffin-
embedded sections from arteries and from tonsils (used as
positive controls). Following rehydration, antigen was un-
masked for 45 minutes at 95°C using Dako Target retrieval
solution (pH 6.0). Endogenous peroxidase was blocked for 10
minutes with Dako peroxidase blocking reagent, and nonspe-
cific binding was blocked for 20 minutes with Dako protein
block. The primary antibodies, mouse monoclonal anti-human
IL-32 (IgG1, clone KU32-09; 1:200 dilution) and rabbit poly-
clonal anti-human IL-32 (1:250 dilution) (Sigma-Aldrich),
were added and incubated for 1 hour at room temperature.
Isotype-matched irrelevant antibodies were used as a negative
control (mouse IgG1 monoclonal antibody [mAb] [ab27479]
and rabbit IgG polyclonal antibody [ab27472]; AbCam).
Following 3 washes with Tris buffered saline, slides were
incubated for 30 minutes with peroxidase-conjugated Dako
EnVision polymer. After 3 further washings, peroxidase activ-
ity was visualized using diaminobenzidine chromogen (Dako),
and slides were lightly counterstained with hematoxylin before
dehydration and mounting in DePex (VWR International).
Sections were analyzed by 2 experienced pathologists
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(AR and AC) who were blinded with regard to subject group.
The number of IL-3–expressing cells was determined by count-
ing IL-32–immunoreactive cells on photomicrographs ob-
tained from 3 randomly obtained high-power microscopic
fields (400 magnification) under a DM2000 optical micro-
scope, using a DFC320 digital camera (Leica). Staining for
IL-32 was scored semiquantitatively on a 4-point scale (range
0–3); a score of 0 represented no or minimal staining, a score
of 1 indicated up to 40% positive cells, a score of 2 indicated up
to 60% positive cells, and a score of 3 represented staining of
60% of the cells (evaluated using 200 magnification).
Flow cytometry for IL-32 on peripheral blood mono-
nuclear cells (PBMCs) isolated from GCA patients. PBMCs,
isolated from heparinized blood samples from 5 GCA patients
and 5 controls, were stimulated with phorbol myristate ace-
tate (1 g/ml) and ionomycin (0.5 g/ml) and incubated
at 37°C in 5% CO2. After 2 hours of incubation, 10 g/ml bre-
feldin A (Sigma) was added and after 16 hours of incubation
PBMCs were collected and stained with mAb. Reagents
used for flow cytometric analysis were peridinin chlorophyll A
protein–conjugated anti-CD4 (Becton Dickinson), mouse
anti-human IL-32 purified antibody (BioLegend), and
phycoerythrin-conjugated anti-mouse IgG (Sigma). Total cells
were incubated with mAb on ice for 30 minutes and washed
twice in phosphate buffered saline that contained 0.1% weight/
volume NaN3. After surface staining, the cells were fixed with
1% w/v paraformaldehyde (Sigma) for 30 minutes at 4°C and
were then permeabilized with a permeabilization solution
(Becton Dickinson) for 10 minutes at room temperature and
stained with antibodies to intracellular antigens. Three-color
flow cytometry was performed using a FACSCalibur (Becton
Dickinson). At least 50,000 cells (events), gated on the lym-
phocyte region, were acquired for each sample. PBMCs were
expressed as the percentage of cells within the lymphocyte
gate. The acquired data were analyzed using CellQuest soft-
ware (Becton Dickinson). IFN- and IL-32–producing T cells
in PBMCs were determined by CD4, IFN, and IL-32 staining,
and subsequent analysis on a FACSCalibur flow cytometer.
Statistical analysis. Statistical analysis of quantitative
variables was performed using the Mann-Whitney rank sum
test. Pearson’s correlation coefficient was utilized to quantify
the associations between the genes of interest. P values less
than 0.05 were considered significant.
RESULTS
Clinical and histologic features. A strong clinical
inflammatory response (fever and weight loss) was ob-
served in 5 patients and a high inflammatory reaction
demonstrated by laboratory results (ESR 85 mm/hour
and hemoglobin 11.0 gm/dl) in 4 patients. Overall, 5
patients had an inflammatory reaction determined by
clinical examination or laboratory analysis. All enrolled
patients had a positive temporal artery biopsy result with
intimal thickening due to proliferation and migration of
vascular smooth muscle cells (VSMCs).
Figure 1. Interleukin-32 (IL-32), IL-1, tumor necrosis factor  (TNF), interferon- (IFN), IL-6, and IL-27p28 genes in inflamed
arteries from patients with giant cell arteritis (GCA). Relative expression of mRNA for IL-32 (A), IL-1 (B), TNF (C), IFN (D),
IL-6 (E), and IL-27p28 (F) in arterial specimens obtained from 11 patients with GCA and 5 control arteries (Ctr A) was quantified
by TaqMan real-time polymerase chain reaction. Bars show the mean  SEM.   P  0.0001 versus control.
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IL-32, IL-1, TNF, IFN, IL-6, and IL-27p28
messenger RNA (mRNA) expression in the temporal
arteries of patients with GCA. We investigated whether
arterial inflammation in GCA patients was characterized
by up-regulation of IL-32 and proinflammatory Th1
cytokines involved in its regulation. As shown in Figure
1A, a marked and significant increase in arterial expres-
sion of IL-32 transcripts was observed in GCA patients
compared with control artery biopsy specimens (mean
SEM 11.16  0.5 and 1.25  0.13; P  0.0001).
Consistent with IL-32 up-regulation, levels of
IL-1, TNF, and IFN were significantly increased in
Figure 2. IL-32 expression in arterial wall. Temporal artery biopsy specimens were obtained from controls (A)
and patients with GCA (B–F) and stained for IL-32. IL-32 expression was observed in the GCA patients, but not
in control arteries. Abundant IL-32 expression was observed in a large number of giant cells present in the wall
of inflamed arteries (arrows in D). Expression of IL-32 was more intense in microvessels scattered through the
inflammatory infiltrates (arrows in F) than in the luminal endothelium (arrows in E). IL-32 vascular smooth
muscle cells were observed in all inflamed arteries (B–F). Representative photomicrographs of 5-m–thick
paraffin-embedded specimens are shown. Original magnification  100 in A–C;  250 in D–F. See Figure 1 for
definitions.
Figure 3. Correlation of immunohistochemical semiquantitative scores for interleukin-32 (IL-32) with number of
inflammation (infl.) parameters and with expression levels of IL-32 mRNA. A, Patients with higher immunohistochem-
ical scores for IL-32 exhibited a higher number of inflammation parameters. B, Semiquantitative IL-32 scores directly
correlated with IL-32 mRNA levels. Values are the mean  SEM.
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GCA patients compared to controls (53.7  4.24 versus
1.32 0.15, 7.16 0.27 versus 1.4 0.33, and 45 8.56
versus 4.2  1.02, respectively; P  0.0001) (Figures
1B–D), indicating the concomitant occurrence of a Th1
response in GCA. IL-32 up-regulation was also accom-
panied by strong IL-6 overexpression in GCA patients
(240  51.12 versus 1.8  0.4; P  0.0001) (Figure 1E).
It is also relevant to note that IL-27p28 showed signifi-
cantly higher transcript levels in GCA patients (241.66
40.11 versus 14  2.5) (Figure 1F).
IL-32 expression in tissue from patients with
GCA. Given the strong up-regulation of IL-32 mRNA in
biopsy specimens from patients with GCA, we next
investigated its protein expression and distribution pat-
Figure 4. Evaluation of IL-32 immunostaining specificity. Representative photomicrographs of randomly
selected 5-m–thick paraffin-embedded sections of temporal artery biopsy specimens obtained from patients with
GCA with low inflammation (A and D), moderate inflammation (B and E), or high inflammation (C and F),
stained with 2 different anti–IL-32 antibodies (antibodies in A–C from BioLegend, in D–F from Sigma-Aldrich)
are shown. The 2 antibodies yielded comparable results. Original magnification  250. See Figure 1 for defini-
tions. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.
com/journal/10.1002/(ISSN)1529-0131.
Figure 5. Th1 lymphocytes are expanded and produce high amounts of IL-32 in GCA. A, Higher percentage of
CD4IFNIL-32 lymphocytes in patients with biopsy-proven GCA than in controls. B, Twofold increase in
IL-32 mean fluorescence intensity on CD4IFN Th1 lymphocytes from GCA patients compared to controls.
Bars show the mean  SEM.   P  0.0455;   P  0.001 versus control. See Figure 1 for definitions.
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tern. Histologically normal arteries did not exhibit sig-
nificant immunostaining for IL-32 (Figure 2A). IL-32
infiltrating cells were detectable only in inflamed arterial
samples from patients with GCA (Figures 2B–F). Semi-
quantitative evaluation of the staining for IL-32 demon-
strated that 6 of the 18 patients with biopsy-proven GCA
had a score of 3, 10 had a score of 2, and 2 had a score
of 1. Patients with higher scores for IL-32 expression
also exhibited a higher number of inflammation param-
eters, as described in Patients and Methods (2 patients
with 0–1 parameters of inflammation each had a score of
1, 10 patients with 2 parameters of inflammation had a
mean  SEM score of 1.62  0.18, and 6 patients with
2 parameters of inflammation had a score of 2.6 
0.24) (Figure 3A). Interestingly, the highest levels of
IL-32 protein expression were observed in those patients
who displayed the highest IL-32 mRNA levels.
The morphologic appearance of IL-32–
infiltrating cells was mainly characterized by a large
cytoplasm and often dendritic morphology, consistent
with a monocyte-derived cell lineage (i.e., macrophages/
dendritic cells). IL-32 giant cells scattered through the
inflammatory infiltrates were also observed in those
patients exhibiting prevalent granulomatous inflamma-
tion (Figure 2D).
Proliferation and migration of VSMCs are the
major determinants of intimal hyperplasia observed in
inflamed arteries (15,16). VSMCs, which have been
demonstrated to play a pivotal role in arterial wall
inflammation through the production of proinflamma-
tory cytokines, exhibited strong positivity for IL-32 in
GCA patients (Figures 2B–F).
Finally, intense staining for IL-32 was observed in
microvessels distributed within the vessel wall of in-
flamed arteries (Figures 2E and F). Since control spec-
imens did not show vessels scattered through arterial
wall, the majority of microvessels identified in the
inflamed arteries were considered to be neovessels re-
sulting from inflammation-dependent angiogenesis.
In order to confirm the specificity of anti–IL-32
immunostaining, we performed a new series of experi-
ments using 2 different antibodies against IL-32 (a
previously used mouse monoclonal and a rabbit poly-
clonal anti-human IL-32) on 3 tissue samples randomly
selected, one with low expression of IL-32, one with
moderate expression, and one with high expression. As
shown in Figure 4, the 2 antibodies worked similarly.
IL-32 production by Th1 lymphocytes among
GCA patient PBMCs. In order to assess whether pe-
ripheral Th1 cells from GCA patients could produce
IL-32, the frequency of IL-32 IFN-producing Th1
CD4 T cells was evaluated in 5 patients with untreated
GCA and in 5 age-matched controls. In GCA patients,
the frequencies of circulating IFNIL-32 Th1 cells
among CD4 T cells were slightly but significantly
expanded compared to controls (mean  SEM 14.33 
0.92% versus 11.58  0.7%; P  0.0455) (Figure 5A). A
2-fold increase in IL-32 mean fluorescence intensity on
CD4IFN Th1 lymphocytes was observed in GCA
patients compared to controls (603.5  27.86 versus
308.8  20; P  0.001) (Figure 5B).
DISCUSSION
IL-32 is a recently described Th1 cytokine that is
mainly produced by natural killer cells, T cells, epithelial
cells, and blood monocytes (4). It is prominently induced
by IFN (4), and it has been demonstrated to be an
important mediator of both innate and adaptive immune
response. Additionally, IL-32 exhibits several properties
typical of proinflammatory cytokines, inducing the re-
lease of cytokines and chemokines (17).
IL-32 overexpression has been demonstrated in
human inflammatory disorders such as RA and Crohn’s
disease. In RA synovial tissue, IL-32 is highly expressed
and induces active osteoclast generation, and its levels
correlate with the severity of inflammation and TNF
expression (9–12). IL-32 expression is also markedly
increased in the inflamed mucosa of patients with in-
flammatory bowel disease compared to unaffected mu-
cosa (8).
Although the extremely small number of patients
enrolled limits the strength of the conclusions, this is the
first reported study to show that IL-32 expression is
markedly up-regulated in the inflamed arteries of pa-
tients with GCA. IL-32 up-regulation was accompanied
by strong overexpression of IL-27p28, which is a potent
and earlier inducer of Th1 polarization (13). IL-27, in
fact, commits naive CD4 T cells to differentiate into
Th1 cells by inducing IL-12 receptor 2 and T-bet (12),
as well as inducing production of Th1 cytokines such as
IL-1 and TNF in monocytes (18,19) and overexpres-
sion of IL-6 in RA fibroblast-like synoviocytes (20). In
this regard, IL-6, the expression of which depends on
IL-27 and IL-32 signaling (21,22), was also up-regulated
in our GCA patients. These findings prompted us to
hypothesize that IL-32 and IL-27p28 could participate in
a positive-feedback mechanism, leading to the induction
and perpetuation of arterial inflammatory immune re-
sponses.
GCA is a chronic vasculitis in which both the
innate and the adaptive immune systems play a patho-
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genetic role (1). Historically, GCA has been considered
as a Th1-mediated disease (2). Recently, Deng et al (3)
have reported a concomitant Th1 and Th17 response in
tissue samples from GCA patients. In our study, IL-32
expression was associated with a strong Th1 inflamma-
tory response, as demonstrated by the increased levels of
IFN and IL-27p28.
IL-32 expression has been demonstrated in nat-
ural killer cells, epithelial and endothelial cells, lympho-
cytes, and blood monocytes (17). Endothelial cells are
key elements in the development of inflammatory infil-
trates through the cytokine-dependent overexpression of
adhesion molecules. Neoangiogenesis is noted in most
GCA specimens (23), and neovessels are mainly where
leukocyte–endothelial cell interactions take place. IL-32
has also been demonstrated to contribute directly to
endothelial cell activation by regulating adhesion mole-
cule expression; our observation of intense IL-32 expres-
sion occurring prevalently in neovessels of inflamed
arteries provides strong evidence for a pivotal role of
IL-32 in the organization of the vascular inflammatory
response.
In GCA, all injury mechanisms have been related
to effector macrophages (16). IL-32 has been demon-
strated to induce giant cell formation from CD14
monocytes (12) and in the present study, macrophages
and giant cells showed intense positivity for IL-32,
emphasizing the central role of these cells in the patho-
genesis of GCA. Macrophages and giant cells produce
platelet-derived growth factor and vascular endothelial
growth factor, which actively induce proliferation of
VSMCs and intimal hyperplasia (15). VSMCs from
inflamed arteries of GCA patients showed a strong
positivity for IL-32 in the present study, suggesting a
direct immunologic participation in arterial inflamma-
tion. The exact role of IL-32 on muscular cell activation
and proliferation, however, needs to be better eluci-
dated.
Sensing of microbial pathogens is primarily me-
diated by the recognition of pathogen-associated molec-
ular patterns, which are conserved structures expressed
by microbes of the same class. The most important of
these recognition systems are the Toll-like receptor
(TLR) and nucleotide-binding oligomerization domain
(NOD) families of proteins (25). IL-32 and IL-27 over-
expression observed in GCA patients could be the result
of innate immune system activation, since IL-32 has
been demonstrated to specifically synergize with NOD1
and NOD2 ligands for the synthesis of IL-1 and IL-6
(21), and IL-27p28 is induced through stimulation of
TLR-3, TLR-4, TLR-7, and TLR-8 (26). In inflamed
arteries, IL-27p28 could induce a cytokine milieu that is
favorable for IL-32 expression through the induction of
IL-32–inducing cytokines, such as IL-1 and TNF;
both IL-32 and IL-27p28 may in turn stimulate Th1
lymphocyte functions, thereby transforming the innate
immunity signals into adaptive immunity responses.
In conclusion, the demonstration of IL-32 over-
expression in inflamed arteries of GCA patients impli-
cates IL-32 as a pathogenetic mediator participating in
the arterial wall inflammation occurring in this disease.
The correlation of IL-32 expression with clinical markers
of disease activity could support a potential use of
therapeutic strategies directed at reducing IL-32 activity
in patients with GCA.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Triolo had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study conception and design. Ciccia, Alessandro, Rizzo, Principe,
Raiata, Cavazza, Guggino, Accardo-Palumbo, Boiardi, Ferrante, Prin-
cipato, Giardina, De Leo, Salvarani, Triolo.
Acquisition of data. Ciccia, Alessandro, Rizzo, Principe, Raiata,
Cavazza, Guggino, Accardo-Palumbo, Boiardi, Ferrante, Principato,
Giardina, De Leo, Salvarani, Triolo.
Analysis and interpretation of data. Ciccia, Alessandro, Guggino,
Accardo-Palumbo, De Leo, Triolo.
REFERENCES
1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and
giant-cell arteritis. Lancet 2008;372:234–45.
2. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine
patterns in patients with polymyalgia rheumatica and giant cell
arteritis. Ann Intern Med 1994;121:484–91.
3. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17
and Th1 T-cell responses in giant cell arteritis. Circulation 2010;
121:906–15.
4. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-
32: a cytokine and inducer of TNF. Immunity 2005;22:131–42.
5. Kobayashi H, Lin PC. Molecular characterization of IL-32 in
human endothelial cells. Cytokine 2009;46:351–8.
6. Kobayashi H, Huang J, Ye F, Shyr Y, Blackwell TS, Lin PC.
Interleukin-32 propagates vascular inflammation and exacer-
bates sepsis in a mouse model. PLoS One 2010;5:e9458.
7. Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF,
Dinarello CA. IL-32-dependent effects of IL-1 on endothelial
cell functions. Proc Natl Acad Sci U S A 2009;106:3883–8.
8. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-
Mitsuyama S, et al. Epithelial overexpression of interleukin-32 in
inflammatory bowel disease. Clin Exp Immunol 2007;149:480–6.
9. Alsaleh G, Sparsa L, Chatelus E, Ehlinger M, Gottenberg JE,
Wachsmann D, et al. Innate immunity triggers IL-32 expression by
fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res
Ther 2010;12:R135.
10. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello
CA, Netea MG, et al. Tumour necrosis factor alpha-driven IL-32
IL-32 IN GIANT CELL ARTERITIS 2103
expression in rheumatoid arthritis synovial tissue amplifies an
inflammatory cascade. Ann Rheum Dis 2011;70:660–7.
11. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B,
Radstake TR, et al. IL-32, a proinflammatory cytokine in rheu-
matoid arthritis. Proc Natl Acad Sci U S A 2006;103:3298–303.
12. Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B. Effect of
interleukin-32 on differentiation of osteoclasts from CD14
monocytes. Arthritis Rheum 2010;62:515–23.
13. Hunter CA. New IL-12-family members: IL-23 and IL-27, cyto-
kines with divergent functions. Nat Rev Immunol 2005;5:521–31.
14. Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B,
Lopez-Soto A, et al. Association between strong inflammatory
response and low risk of developing visual loss and other cranial
ischemic complications in giant cell (temporal) arteritis. Arthritis
Rheum 1998;41:26–32.
15. Ly KH, Regent A, Tamby MC, Mouthon L. Pathogenesis of giant
cell arteritis: more than just an inflammatory condition? Autoim-
mun Rev 2010;9:635–45.
16. Piggott K, Biousse V, Newman NJ, Goronzy JJ, Weyand CM.
Vascular damage in giant cell arteritis. Autoimmunity 2009;42:
596–604.
17. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role
in disease. Ann Rheum Dis 2006;65 Suppl III:iii61–4.
18. Beadling C, Slifka MK. Regulation of innate and adaptive immune
responses by the related cytokines IL-12, IL-23, and IL-27. Arch
Immunol Ther Exp (Warsz) 2006;54:15–24.
19. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via
STAT1 and suppresses IL-10 production but the inflammatory
functions of IL-27 are abrogated by TLRs and p38. J Immunol
2008;180:6325–33.
20. Wong CK, Chen dP, Tam LS, Li EK, Yin YB, Lam CW. Effects of
inflammatory cytokine IL-27 on the activation of fibroblast-like
synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010;12:
R129.
21. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS,
et al. IL-32 synergizes with nucleotide oligomerization domain
(NOD) 1 and NOD2 ligands for IL-1 and IL-6 production
through a caspase 1-dependent mechanism. Proc Natl Acad Sci U
S A 2005;102:16309–14.
22. Guzzo C, Che Mat NF, Gee K. Interleukin-27 induces a STAT1/3-
and NF-B-dependent proinflammatory cytokine profile in human
monocytes. J Biol Chem 2010;285:24404–11.
23. Cid MC, Cebrian M, Font C, Coll-Vinent B, Hernandez-Rodri-
guez J, Esparza J, et al. Cell adhesion molecules in the develop-
ment of inflammatory infiltrates in giant cell arteritis: inflamma-
tion-induced angiogenesis as the preferential site of
leukocyte–endothelial cell interactions. Arthritis Rheum 2000;43:
184–94.
24. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis.
Arthritis Rheum 1999;42:844–53.
25. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know
about danger. J Leukoc Biol 2007;81:1–5.
26. Villarino AV, Huang E, Hunter CA. Understanding the pro- and
anti-inflammatory properties of IL-27. J Immunol 2004;173:
715–20.
2104 CICCIA ET AL
